Paul D'Angio

All filings by Paul D'Angio on record concern NexImmune, Inc. We count 3 filings, every one of them for a trade on 17 February 2021.

No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.

The newest entry dates from 19 February 2021: a transaction, in NexImmune, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.